"If we can attack the disease before those symptoms start, we're doing a major service to the patient and to society." ...

We are 90% funded by individual contributions. That means you create the reader-powered journalism that cuts through the noise, and delivers the trusted information Connecticut cares about. Imagine ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit. Undergoing biomarker testing may help ...

Which is why, in part, the promise — and boom — of blood biomarkers testing has moved quickly in the past three to five years, researchers say. The FDA recently cleared two blood tests that detect ...

PUBLIC LIFE. IOWA CANCER SURVIVORS ARE GATHERING AT THE STATE HOUSE THIS AFTERNOON AS KCCI ETHAN HUMBLE EXPLAINS THEIR MEETING WITH LAWMAKERS TO DISCUSS WHAT CAN BE DONE TO REDUCE THE RISK OF THAT ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Please provide your email address to receive an email when new articles are posted on . Biomarker testing appeared inconsistent, with rates not reflecting guidelines. Less than 25% of oncologists ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...